Effects of long term low dose azithromycin in patients with non-cystic fibrosis bronchiectasis

A. Dwarakanath, J. Nanjappa, C. Taylor, A. Fennerty (United Kingdom)

Source: Annual Congress 2010 - New aspects of treatment of lower respiratory tract infections
Session: New aspects of treatment of lower respiratory tract infections
Session type: Oral Presentation
Number: 5578
Disease area: Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Dwarakanath, J. Nanjappa, C. Taylor, A. Fennerty (United Kingdom). Effects of long term low dose azithromycin in patients with non-cystic fibrosis bronchiectasis. Eur Respir J 2010; 36: Suppl. 54, 5578

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Effects of long-term azithromycin treatment in patients with non-cystic fibrosis stable bronchiectasis
Source: Annual Congress 2007 - Infectious lung and pleural diseases
Year: 2007


Usefulness of long term treatment with azithromycin in patients with bronchiectasis (non cystic fibrosis)
Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections
Year: 2010


Effect of azithromycin on FEV1 and exacerbation frequency in adult non-cystic fibrosis bronchiectasis
Source: Eur Respir J 2007; 30: Suppl. 51, 528s
Year: 2007

The effect of long term low dose azithromycin on symptoms and lung function in pulmonary sarcoidosis
Source: Annual Congress 2008 - Sarcoidosis: pathophysiology and severity
Year: 2008



Aerozolized colistin therapy in non-cystic fibrosis patients with bronchiectasis
Source: Eur Respir J 2001; 18: Suppl. 33, 266s
Year: 2001

Efficacy and safety of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis
Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis
Year: 2011

Effect of high dose tobramicin (TOBI®) inhalation on respiratory values in cystic fibrosis
Source: Eur Respir J 2003; 22: Suppl. 45, 503s
Year: 2003

Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis
Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis
Year: 2011

Evaluation of inhaled dry powder tobramycin free base in non-cystic fibrosis bronchiectasis patients
Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections
Year: 2016


Inhaled steroids in children with non-cystic fibrosis bronchiectasis
Source: Eur Respir J 2004; 24: Suppl. 48, 392s
Year: 2004

Long-term administration of aerosolised tobramycin in patients with cystic fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 619s
Year: 2005

Long-term treatment with low-dose azithromycin reduces cough, sputum production and exacerbations in patients with idiopathic diffuse bronchiectasis
Source: Eur Respir J 2004; 24: Suppl. 48, 707s
Year: 2004

Inhaled antibiotics in non-cystic fibrosis bronchiectasis: better than oral antibiotics?
Source: International Congress 2016 – PG13 Inhaled antibiotics in respiratory infections
Year: 2016



Once-daily tobramycin in the treatment of adult patients with cystic fibrosis
Source: Eur Respir J 2002; 19: 303-309
Year: 2002



Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: Evaluation of exacerbations and lung function
Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring
Year: 2016


Adherence with inhaled colistimethate sodium during a 6 month study in patients with non-cystic fibrosis bronchiectasis
Source: Annual Congress 2013 –Treating bronchiectasis in respiratory patients
Year: 2013


Treatment efficacy of idiopathic pulmonary fibrosis depending on the dose difference of pirfenidone
Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis
Year: 2020

Safety, tolerability and efficacy of intravenous aminophylline in adult patients with pulmonary exacerbations of cystic fibrosis
Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects
Year: 2014

Treatment of exacerbations of fibrotic idiopathic interstitial pneumonias with cyclophosphamide and corticosteroids
Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis
Year: 2010


Health status impact of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis
Source: Annual Congress 2011 - Pseudomonas aeruginosa infection and non-cystic fibrosis bronchiectasis
Year: 2011